A New Generation of Targeted Therapies Is Transforming Treatment for Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is an autoimmune condition in which the immune system produces antibodies that mistakenly target and destroy platelets, the tiny blood cells essential for normal clotting. It affects between 2 and 5 people per 100,000 worldwide, and approximately 30% of patients go on to develop chronic or refractory ITP that resists standard treatment. In ITP, B cells generate antibodies against proteins on the platelet surface, and those antibody-coated platelets are rapidly cleared by macrophages in the spleen and liver. At the same time, the antibodies impair megakaryocytes in the bone marrow, reducing the production of new platelets. The result is a simultaneous increase in platelet destruction and a decrease in platelet production, leading to low counts and increased bleeding risk ranging from minor bruising to serious internal hemorrhage.

For decades, treatment relied on corticosteroids as the first step, followed by splenectomy if steroids failed. Both approaches carry significant limitations. Short-term steroid therapy improves platelet counts in 60 to 80 percent of patients, but roughly half relapse after the dose is reduced, and long-term use raises the risk of infections, osteoporosis, and metabolic complications. Splenectomy, once considered the gold standard second-line approach, carries an invasive surgical risk and a 20 to 30 percent relapse rate, leading clinicians to reserve it for patients who fail or cannot tolerate medications. A comprehensive review published in Frontiers in Pharmacology in August 2026 evaluates the generation of targeted drugs that have emerged to fill this gap, drawing on trial data from May 2010 through May 2026.

One of the most established newer categories is thrombopoietin receptor agonists (TPO-RAs), which stimulate the bone marrow to produce more platelets and partially compensate for the increased immune-mediated destruction. Romiplostim, eltrombopag, and avatrombopag all work through this mechanism. A Phase 3 trial of romiplostim in China found that 85.3% of patients reached platelet counts above 20 x 10^9 per liter at 22 weeks compared to none in the placebo group. A large real-world study of avatrombopag in 268 patients reported a 90% therapeutic response rate among those with low baseline platelet counts, with 87.6% of continuing patients maintaining that response. These agents have now become a well-established second-line option and are explicitly recommended in current international guidelines.

BTK inhibitors represent a newer and growing category. Rilzabrutinib, an oral BTK inhibitor that blocks B-cell activation and the macrophage-mediated destruction of platelets, was evaluated in the Phase 3 LUNA 3 trial involving 133 patients with persistent or chronic ITP. Twenty-three percent of patients on rilzabrutinib achieved a durable platelet response compared to zero in the placebo group, and all secondary efficacy endpoints also favored the drug. Adverse effects were generally mild, mostly grade 1 or 2. Fostamatinib, a SYK inhibitor working at a different point in the destruction pathway, showed a 79% overall response rate in a real-world series of 138 patients and is now an explicitly recommended second-line option when TPO-RAs or rituximab are not appropriate. Efgartigimod, which reduces harmful IgG antibody levels by blocking their recycling through the FcRn receptor, produced a sustained response in 22.1% of patients in the Phase 3 ADVANCE IV trial compared to 6.7% with placebo, with a notably lower rate of bleeding events in the treated group.

For patients who have failed multiple lines of therapy, early-stage cell-based approaches are offering new avenues. CD19-directed CAR-T cells, which selectively eliminate the B cells responsible for generating antiplatelet antibodies, demonstrated rapid platelet recovery in a preclinical ITP model. Umbilical cord-derived mesenchymal stem cells showed a 44% overall response rate in an early Phase 1 trial of 18 patients with refractory ITP, with no severe adverse events, and appear to modulate the immune environment in addition to supporting platelet production. Researchers are also exploring combination strategies, such as pairing eltrombopag with diacerein, which produced a 44% remission rate at 15 days compared to just 13% with eltrombopag alone in a Phase 2 study. The review makes clear that ITP is no longer a condition with only two or three treatment choices, and that matching the right therapy to each patient's history, disease duration, and individual risk factors is increasingly achievable.